Combination of bendamustine and entinostat synergistically inhibits proliferation of multiple myeloma cells via induction of apoptosis and DNA damage response

Cancer Letters

Volumn 335, Issue 2, 2013, Pages 343-350

  Cai, Bo ^a,b   Lyu, Hui ^b   Huang, Jingcao ^b   Wang, Shuiliang ^b   Lee, Choon Kee ^b,c   Gao, Chunji ^a   Liu, Bolin ^b  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^c Montrose Memorial Hospital   (United States)

Author keywords

Apoptosis; Bendamustine; DNA damage; Entinostat; Multiple myeloma

Indexed keywords

BENDAMUSTINE; CASPASE 3; CASPASE 8; CHECKPOINT KINASE 2; ENTINOSTAT; HISTONE H2AX; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE S PHASE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA DAMAGE; DOUBLE STRANDED DNA BREAK; DRUG POTENTIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MYELOMA CELL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; WESTERN BLOTTING;

APOPTOSIS; BENZAMIDES; CASPASE 3; CASPASE 8; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DNA DAMAGE; DNA REPAIR; DRUG COMBINATIONS; DRUG SYNERGISM; G2 PHASE CELL CYCLE CHECKPOINTS; HISTONE DEACETYLASE INHIBITORS; HISTONES; HUMANS; MULTIPLE MYELOMA; NITROGEN MUSTARD COMPOUNDS; POLY(ADP-RIBOSE) POLYMERASES; PROTEIN-SERINE-THREONINE KINASES; PYRIDINES; S PHASE CELL CYCLE CHECKPOINTS;

EID: 84878257272     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2013.02.046     Document Type: Article

References (38)

1. Kyle R.A., Rajkumar S.V. Multiple myeloma. N. Engl. J. Med. 2004, 351:1860-1873.
2. Anderson K.C. New insights into therapeutic targets in myeloma. Hemat. Am. Soc. Hemat. Educ. Program. 2011, 2011:184-190.
3. Leoni L.M., Bailey B., Reifert J., Bendall H.H., Zeller R.W., Corbeil J., Elliott G., Niemeyer C.C. Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents. Clin. Cancer Res. 2008, 14:309-317.
4. Kalaycio M. Bendamustine: a new look at an old drug. Cancer 2009, 115:473-479.
5. Chow K.U., Boehrer S., Geduldig K., Krapohl A., Hoelzer D., Mitrou P.S., Weidmann E. In vitro induction of apoptosis of neoplastic cells in low-grade non-Hodgkin's lymphomas using combinations of established cytotoxic drugs with bendamustine. Haematologica 2001, 86:485-493.
6. Kanekal S., Crain B., Elliott G., Multani P.S. SDX-105 (Treanda (TM)) enhances the tumor growth inhibitory effect of rituximab in Daudi lymphoma xenografts. Blood 2004, 104:229b.
7. Fischer K., Cramer P., Busch R., Stilgenbauer S., Bahlo J., Schweighofer C.D., Bottcher S., Staib P., Kiehl M., Eckart M.J., Kranz G., Goede V., Elter T., Buhler A., Winkler D., Kneba M., Dohner H., Eichhorst B.F., Hallek M., Wendtner C.M. Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J. Clin. Oncol. 2011, 29:3559-3566.
8. Visani G., Malerba L., Stefani P.M., Capria S., Galieni P., Gaudio F., Specchia G., Meloni G., Gherlinzoni F., Giardini C., Falcioni S., Cuberli F., Gobbi M., Sarina B., Santoro A., Ferrara F., Rocchi M., Ocio E.M., Caballero M.D., Isidori A. BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant/relapsed lymphoma patients. Blood 2011, 118:3419-3425.
9. Fowler N., Kahl B.S., Lee P., Matous J.V., Cashen A.F., Jacobs S.A., Letzer J., Amin B., Williams M.E., Smith S., Saleh A., Rosen P., Shi H., Parasuraman S., Cheson B.D. Bortezomib, bendamustine, and rituximab in patients with relapsed or refractory follicular lymphoma: the phase II VERTICAL study. J. Clin. Oncol. 2011, 29:3389-3395.
10. Lentzsch S., O'Sullivan A., Kennedy R.C., Abbas M., Dai L., Pregja S.L., Burt S., Boyiadzis M., Roodman G.D., Mapara M.Y., Agha M., Waas J., Shuai Y., Normolle D., Zonder J.A. Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation study. Blood 2012, 119:4608-4613.
11. Ramasamy K., Hazel B., Mahmood S., Corderoy S., Schey S. Bendamustine in combination with thalidomide and dexamethasone is an effective therapy for myeloma patients with end stage renal disease. Br. J. Haematol. 2011, 155:632-634.
12. Jones P.A., Baylin S.B. The epigenomics of cancer. Cell 2007, 128:683-692.
13. Glozak M.A., Seto E. Histone deacetylases and cancer. Oncogene 2007, 26:5420-5432.
14. Lane A.A., Chabner B.A. Histone deacetylase inhibitors in cancer therapy. J. Clin. Oncol. 2009, 27:5459-5468.
15. Knipstein J., Gore L. Entinostat for treatment of solid tumors and hematologic malignancies. Expert Opin. Inv. Drug. 2011, 20:1455-1467.
16. Huang X., Gao L., Wang S., Lee C.K., Ordentlich P., Liu B. HDAC inhibitor SNDX-275 induces apoptosis in erbB2-overexpressing breast cancer cells via down-regulation of erbB3 expression. Cancer Res. 2009, 69:8403-8411.
17. Huang X., Wang S., Lee C.K., Yang X., Liu B. HDAC inhibitor SNDX-275 enhances efficacy of trastuzumab in erbB2-overexpressing breast cancer cells and exhibits potential to overcome trastuzumab resistance. Cancer Lett. 2011, 307:72-79.
18. Lee C.K., Wang S., Huang X., Ryder J., Liu B. HDAC inhibition synergistically enhances alkylator-induced DNA damage responses and apoptosis in multiple myeloma cells. Cancer Lett. 2010, 296:233-240.
19. Chou T.C., Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul. 1984, 22:27-55.
20. Chou T.C., Talaly P. A simple generalized equation for the analysis of multiple inhibitions of Michaelis-Menten kinetic systems. J. Biol. Chem. 1977, 252:6438-6442.
21. Cheson B.D., Rummel M.J. Bendamustine: rebirth of an old drug. J. Clin. Oncol. 2009, 27:1492-1501.
22. Montillo M., Ricci F., Tedeschi A., Vismara E., Morra E. Bendamustine: new perspective for an old drug in lymphoproliferative disorders. Expert Rev. Hematol. 2010, 3:131-148.
23. Stewart A.K. Novel therapies for relapsed myeloma. Hematol. Am. Soc. Hematol. Educ. Program 2009, 578-586.
24. Badros A., Burger A.M., Philip S., Niesvizky R., Kolla S.S., Goloubeva O., Harris C., Zwiebel J., Wright J.J., Espinoza-Delgado I., Baer M.R., Holleran J.L., Egorin M.J., Grant S. Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma. Clin. Cancer Res. 2009, 15:5250-5257.
25. Galli M., Salmoiraghi S., Golay J., Gozzini A., Crippa C., Pescosta N., Rambaldi A. A phase II multiple dose clinical trial of histone deacetylase inhibitor ITF2357 in patients with relapsed or progressive multiple myeloma. Ann. Hematol. 2010, 89:185-190.
26. Gimsing P., Hansen M., Knudsen L.M., Knoblauch P., Christensen I.J., Ooi C.E., Buhl-Jensen P. A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia. Eur. J. Haematol. 2008, 81:170-176.
27. Wolf J.L., Siegel D., Goldschmidt H., Hazell K., Bourquelot P.M., Bengoudifa B.R., Matous J., Vij R., de Magalhaes-Silverman M., Abonour R., Anderson K.C., Lonial S. Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma. Leuk. Lymphoma 2012, 53:1820-1823.
28. Sanchez E., Shen J., Steinberg J., Li M., Wang C., Bonavida B., Chen H., Li Z.W., Berenson J.R. The histone deacetylase inhibitor LBH589 enhances the anti-myeloma effects of chemotherapy in vitro and in vivo. Leuk Res 2011, 35:373-379.
29. Rasschaert M., Schrijvers D., Van den Brande J., Dyck J., Bosmans J., Merkle K., Vermorken J.B. A phase I study of bendamustine hydrochloride administered once every 3 weeks in patients with solid tumors. Anticancer Drug. 2007, 18:587-595.
30. Ryan Q.C., Headlee D., Acharya M., Sparreboom A., Trepel J.B., Ye J., Figg W.D., Hwang K., Chung E.J., Murgo A., Melillo G., Elsayed Y., Monga M., Kalnitskiy M., Zwiebel J., Sausville E.A. Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma. J. Clin. Oncol. 2005, 23:3912-3922.
31. Niesvizky R., Ely S., Mark T., Aggarwal S., Gabrilove J.L., Wright J.J., Chen-Kiang S., Sparano J.A. Phase 2 trial of the histone deacetylase inhibitor romidepsin for the treatment of refractory multiple myeloma. Cancer 2011, 117:336-342.
32. Richardson P., Mitsiades C., Colson K., Reilly E., McBride L., Chiao J., Sun L., Ricker J., Rizvi S., Oerth C., Atkins B., Fearen I., Anderson K., Siegel D. Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma. Leuk. Lymphoma 2008, 49:502-507.
33. Kikuchi J., Wada T., Shimizu R., Izumi T., Akutsu M., Mitsunaga K., Noborio-Hatano K., Nobuyoshi M., Ozawa K., Kano Y., Furukawa Y. Histone deacetylases are critical targets of bortezomib-induced cytotoxicity in multiple myeloma. Blood 2010, 116:406-417.
34. Pei X.Y., Dai Y., Grant S. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors. Clin. Cancer Res. 2004, 10:3839-3852.
35. Catley L., Weisberg E., Kiziltepe T., Tai Y.T., Hideshima T., Neri P., Tassone P., Atadja P., Chauhan D., Munshi N.C., Anderson K.C. Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells. Blood 2006, 108:3441-3449.
36. Miller C.P., Singh M.M., Rivera-Del Valle N., Manton C.A., Chandra J. Therapeutic strategies to enhance the anticancer efficacy of histone deacetylase inhibitors. J. Biomed. Biotechnol. 2011, 2011:514261.
37. Venkitaraman A.R. Modifying chromatin architecture during the response to DNA breakage. Crit. Rev. Biochem. Mol. Biol. 2010, 45:2-13.
38. Mahindra A., Cirstea D., Raje N. Novel therapeutic targets for multiple myeloma. Future Oncol. 2010, 6:407-418.